Ferrata Storti Foundation
Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to R
Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?
Prof. Camillo PORTA CURRICULUM VITÆ, and LIST OF SCIENTIFIC PUBLICATIONS
Italy. Pavia. Courtyard in University of Pavia. From left to right, statues: Luigi Porta Pavese (1800-1875), Antonio Maria Bordoni (1789-1860) and Bartolomeo Panizza (1785-1667 Stock Photo - Alamy
MP14-12 STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR TREATMENT OF RENAL CELL CARCINOMA (RCC) WITH INFERIOR VENA CAVA TUMOR
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Revie
Recent advances in the frontline treatment of metastatic renal cell carcinoma
PDF) Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
TIVO- 3 Key Activities
PDF) RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia. - ppt download
PDF) Targeting PI3K/Akt/mTOR signaling in cancer
PDF) Management of poor-risk metastatic renal cell carcinoma: Current approaches, the role of temsirolimus and future directions
The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)
Camillo Porta - insalutenews.it
PPT - HOW TO SELECT AMONG AVAILABLE OPTIONS FOR THE TREATMENT OF ADVANCED RCC: PowerPoint Presentation - ID:2655374
Intervista Prof. Camillo Porta - YouTube
Loop | Camillo Porta
Procopio e Porta, confronto sul carcinoma renale e non solo - YouTube
5-Methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo?
Tolerability of first-line therapy for metastatic renal cell carcinoma
